Impacts of X-linked Retinitis Pigmentosa and Patient Pathways in European Countries: Results from the Cross-sectional EXPLORE XLRP-1 Physician Survey-Reference-Cited by-同舟云学术

Impacts of X-linked Retinitis Pigmentosa and Patient Pathways in European Countries: Results from the Cross-sectional EXPLORE XLRP-1 Physician Survey

Published:2024-07-08 Issue:8 Volume:41 Page:3378-3395
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Pungor Katalin^ORCID,Lee Jennifer,Denee Tom^ORCID,Kambarov Yerkebulan^ORCID,Nissinen Riikka,Ampeh Kevin,Pellegrini Marco^ORCID,Parmeggiani Francesco^ORCID

Funder

Janssen Pharmaceuticals

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12325-024-02935-5.pdf

Reference35 articles.

1. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. Lancet. 2006;368(9549):1795–809. https://doi.org/10.1016/S0140-6736(06)69740-7.

2. Ferrari S, Di Iorio E, Barbaro V, Ponzin D, Sorrentino FS, Parmeggiani F. Retinitis pigmentosa: genes and disease mechanisms. Curr Genom. 2011;12(4):238–49. https://doi.org/10.2174/138920211795860107.

3. Chivers M, Li N, Pan F, Wieffer H, Slowik R, Leartsakulpanitch J. The Burden of X-linked retinitis pigmentosa on patients and society: a narrative literature review. Clinicoecon Outcomes Res. 2021;13:565–72. https://doi.org/10.2147/CEOR.S297287.

4. Fahim AT, Sullivan LS, Bowne SJ, et al. X-chromosome inactivation is a biomarker of clinical severity in female carriers of RPGR-associated X-linked retinitis pigmentosa. Ophthalmol Retina. 2020;4(5):510–20. https://doi.org/10.1016/j.oret.2019.11.010.

5. Martinez-Fernandez De La Camara C, Nanda A, Salvetti AP, Fischer MD, MacLaren RE. Gene therapy for the treatment of X-linked retinitis pigmentosa. Expert Opin Orphan Drugs. 2018; 6(3):167–177. https://doi.org/10.1080/21678707.2018.1444476.